CClinicalTrials.gg
CompletedNCT04874792COVID-19Updated May 6, 2021

Clinical Characteristics of Deceased With COVID-19

An observational study in Covid19, sponsored by Dhaka Medical College. Completed at 1 site in Bangladesh. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by Dhaka Medical College · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
282
Ages
14 Years and older
Sex
All
01

Study summary

This study aims to describe the clinical characteristics of patients who died from COVID-19 in the largest hospital in Bangladesh to understand the risk associated with COVID-19 related mortality in this region. This is a retrospective study where a review of hospital records of patients will be done who died from COVID-19 in Dhaka Medical College Hospital from 3rd May to 31 August 2020. All available demographic, clinical, laboratory information, radiological feature, and patients' management will be retrieved from the record section to be analyzed and described.

Read the detailed description

In this retrospective observational study, every consecutive patient who died and tested positive for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Dhaka Medical College Hospital from 2nd May 2020 to 31 August 2020 were included. The paper files of patients were retrieved from the record section of the hospital as only a paper-based recording is maintained in the hospital. Patients with suspected COVID-19 were excluded from the study who tested negative for Reverse Transcriptase Polymerase Chain Reaction (RT PCR for SARS-CoV-2).

A preformed case record form (CRF) was used to collect all available demographic, clinical information including presentation, investigation, and treatment from hospital paper file from the record section. The severity of disease for COVID-19 was classified according to National Guidelines on Clinical Management of COVID-19 Version 8.0, 5 November 2020. The mild disease was defined as an individual with COVID-19 with prodromal symptoms without dyspnea and radiological abnormality. The moderate disease was defined as abnormal chest imaging with the saturation of oxygen ≥ 90% and severe disease was denied as saturation of oxygen less than 90%. All data were summarized, analyzed with SPPS 26.

RT PCR for SARS-CoV-2 assay is done in the virology department of Dhaka Medical College to detect SARS-Cov-2 RNA from samples taken from suspected patients. Nasopharyngeal swabs and the oropharyngeal swab were taken from patients. Biochemical, hematological investigations are done in the clinical pathology department of the hospital and paper reports are sent to respective patients' files. Laboratory measurements were collected for analysis which is available in the file of deceased patients in the record section.

02

Conditions studied

  • Covid19

Browse trials for

Keywords

  • COVID19
  • Clinical Characteristics
  • Deceased
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 282 is close to the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Dhaka Medical College is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients died from COVID-19 in Dhaka Medical College Hospital confirmed by Real-Time reverse transcription Polymerase Chain Reaction during the period from 3rd May 2020 to 31st August 2020.

Inclusion criteria

  • All Patients died from COVID-19 confirmed with rt PCR for SARS-CoV-2

Exclusion criteria

Exclusion Criteria:

  • Suspected COVID-19 patients negative for rt PCR for SARS-CoV-2 and
  • Age less than 14 year
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
282 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Clinical Characteristics

    Demography, Clinical presentation, Treatment

    Time frame: 03/05/2020 to 31/08/20

Secondary outcomes

  1. Duration from admission to death

    Duration of Hospitalization from admission to death in different comorbidity and disease severity

    Time frame: 03/05/2020 to 31/08/20

07

Study locations

1 site
  • Dhaka Medical College Hospital
    Dhaka, Bangladesh
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04874792
Lead sponsor
Dhaka Medical College
Responsible party
Mohammad Mahfuzul Hoque (Assistant Professor, Dhaka Medical College) — Principal investigator
First posted
May 6, 2021
Start date
Jul 1, 2020
Primary completion
Nov 30, 2020
Completion
Dec 31, 2020
Last update
May 6, 2021

Study contacts

Mohammad M Hoque, FCPS
principal investigator · Assistant Professor of Medicine, Dhaka Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion